tiprankstipranks
Biogen Inc. (DE:IDP)
NASDAQ:IDP
Germany Market
IDP
Biogen
RESEARCH TOOLSreports

Biogen (IDP) Stock Forecast & Price Target

6 Followers
See the Price Targets and Ratings of:

IDP Analyst Ratings

Moderate Buy
26Ratings
Moderate Buy
16 Buy
9 Hold
1 Sell
Based on 26 analysts giving stock ratings to
Biogen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IDP Stock 12 Month Forecast

Average Price Target

€191.42
▲(27.17% Upside)
Based on 26 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is €191.42 with a high forecast of €238.58 and a low forecast of €130.14. The average price target represents a 27.17% change from the last price of €150.52.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"104":"€104","239":"€239","137.75":"€137.8","171.5":"€171.5","205.25":"€205.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":238.58169775,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€238.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":191.4174480790909,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€191.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130.1354715,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€130.14</span>\n  </div></div>","useHTML":true}}],"tickPositions":[104,137.75,171.5,205.25,239],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,165.12,170.77089982692308,176.42179965384616,182.07269948076924,187.7235993076923,193.37449913461538,199.02539896153846,204.67629878846154,210.32719861538462,215.97809844230767,221.62899826923075,227.27989809615383,232.9307979230769,{"y":238.58169775,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,165.12,167.14288062146852,169.16576124293707,171.18864186440558,173.21152248587413,175.23440310734264,177.2572837288112,179.2801643502797,181.30304497174825,183.32592559321677,185.3488062146853,187.37168683615383,189.39456745762237,{"y":191.4174480790909,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,165.12,162.4288824230769,159.73776484615385,157.04664726923076,154.3555296923077,151.6644121153846,148.97329453846154,146.28217696153845,143.5910593846154,140.8999418076923,138.20882423076924,135.51770665384615,132.82658907692309,{"y":130.1354715,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":114.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.95,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.45,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.46,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165.12,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€238.58Average Price Target€191.42Lowest Price Target€130.14
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on DE:IDP
Ami Fadia
Needham
Needham
€221.23
Buy
46.98%
Upside
Upgraded
06/08/26
Biogen upgraded to Buy from Hold at NeedhamBiogen upgraded to Buy from Hold at Needham
Piper Sandler Analyst forecast on DE:IDP
David Amsellem
Piper Sandler
Piper Sandler
€195.2
Buy
29.69%
Upside
Reiterated
05/29/26
Analysts Offer Insights on Healthcare Companies: Savara (NASDAQ: SVRA) and Biogen (NASDAQ: BIIB)
RBC Capital Analyst forecast on DE:IDP
Brian Abrahams
RBC Capital
RBC Capital
€192.6→€196.94
Buy
30.84%
Upside
Reiterated
05/27/26
RBC Capital Reaffirms Their Buy Rating on Biogen (BIIB)
William Blair Analyst forecast on DE:IDP
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/22/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Bicara Therapeutics Inc. (NASDAQ: BCAX)
Wells Fargo Analyst forecast on DE:IDP
Mohit Bansal
Wells Fargo
Wells Fargo
€216.89
Buy
44.10%
Upside
Reiterated
05/22/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on DE:IDP
Laura Chico
Wedbush
Wedbush
€170.04
Hold
12.97%
Upside
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Cormedix (NASDAQ: CRMD) and Biogen (NASDAQ: BIIB)
Truist Financial Analyst forecast on DE:IDP
Danielle Brill
Truist Financial
Truist Financial
―
Hold
―
Reiterated
05/15/26
Analysts Conflicted on These Healthcare Names: Aquestive Therapeutics (NASDAQ: AQST), Pyxis Oncology (NASDAQ: PYXS) and Biogen (NASDAQ: BIIB)
Goldman Sachs Analyst forecast on DE:IDP
Salveen Richter
Goldman Sachs
Goldman Sachs
€206.48→€216.89
Buy
44.10%
Upside
Reiterated
05/15/26
Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250
Canaccord Genuity Analyst forecast on DE:IDP
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€212.55
Buy
41.21%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Sol-Gel Technologies (NASDAQ: SLGL) and Aveanna Healthcare Holdings (NASDAQ: AVAH)
Evercore ISI Analyst forecast on DE:IDP
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Initiated
05/15/26
Biogen resumed with an Outperform at Evercore ISIBiogen resumed with an Outperform at Evercore ISI
UBS Analyst forecast on DE:IDP
Michael Yee
UBS
UBS
€195.2
Buy
29.69%
Upside
Reiterated
05/15/26
Biogen Buy Rating Reiterated as Tau Data Eases Overhang; Price Target Maintained at $225
H.C. Wainwright Analyst forecast on DE:IDP
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€205.61
Buy
36.60%
Upside
Reiterated
05/14/26
Biogen Buy Rating Reiterated as CELIA Phase 2 Diranersen Data De-Risk Tau Strategy and Support Unchanged $237 Price Target
Bank of America Securities Analyst forecast on DE:IDP
Jason Zemansky
Bank of America Securities
Bank of America Securities
€176.12
Hold
17.01%
Upside
Reiterated
05/14/26
Biogen Rated Hold as Analyst Cites Mixed Alzheimer’s Data and Commercial Hurdles; $203 Price Target Reiterated
Morgan Stanley Analyst forecast on DE:IDP
Terence Flynn
Morgan Stanley
Morgan Stanley
€178.72
Hold
18.73%
Upside
Reiterated
05/14/26
Hold Rating Maintained on Biogen as BIIB080 Moves to Phase 3; Risk-Reward Seen Balanced with Unchanged $206 Price Target
TD Cowen Analyst forecast on DE:IDP
Phil Nadeau
TD Cowen
TD Cowen
€186.53
Buy
23.92%
Upside
Reiterated
05/14/26
TD Cowen Sticks to Their Buy Rating for Biogen (BIIB)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on DE:IDP
Ami Fadia
Needham
Needham
€221.23
Buy
46.98%
Upside
Upgraded
06/08/26
Biogen upgraded to Buy from Hold at NeedhamBiogen upgraded to Buy from Hold at Needham
Piper Sandler Analyst forecast on DE:IDP
David Amsellem
Piper Sandler
Piper Sandler
€195.2
Buy
29.69%
Upside
Reiterated
05/29/26
Analysts Offer Insights on Healthcare Companies: Savara (NASDAQ: SVRA) and Biogen (NASDAQ: BIIB)
RBC Capital Analyst forecast on DE:IDP
Brian Abrahams
RBC Capital
RBC Capital
€192.6→€196.94
Buy
30.84%
Upside
Reiterated
05/27/26
RBC Capital Reaffirms Their Buy Rating on Biogen (BIIB)
William Blair Analyst forecast on DE:IDP
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/22/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Bicara Therapeutics Inc. (NASDAQ: BCAX)
Wells Fargo Analyst forecast on DE:IDP
Mohit Bansal
Wells Fargo
Wells Fargo
€216.89
Buy
44.10%
Upside
Reiterated
05/22/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on DE:IDP
Laura Chico
Wedbush
Wedbush
€170.04
Hold
12.97%
Upside
Reiterated
05/18/26
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (NASDAQ: KROS), Cormedix (NASDAQ: CRMD) and Biogen (NASDAQ: BIIB)
Truist Financial Analyst forecast on DE:IDP
Danielle Brill
Truist Financial
Truist Financial
―
Hold
―
Reiterated
05/15/26
Analysts Conflicted on These Healthcare Names: Aquestive Therapeutics (NASDAQ: AQST), Pyxis Oncology (NASDAQ: PYXS) and Biogen (NASDAQ: BIIB)
Goldman Sachs Analyst forecast on DE:IDP
Salveen Richter
Goldman Sachs
Goldman Sachs
€206.48→€216.89
Buy
44.10%
Upside
Reiterated
05/15/26
Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250
Canaccord Genuity Analyst forecast on DE:IDP
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€212.55
Buy
41.21%
Upside
Reiterated
05/15/26
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Sol-Gel Technologies (NASDAQ: SLGL) and Aveanna Healthcare Holdings (NASDAQ: AVAH)
Evercore ISI Analyst forecast on DE:IDP
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Initiated
05/15/26
Biogen resumed with an Outperform at Evercore ISIBiogen resumed with an Outperform at Evercore ISI
UBS Analyst forecast on DE:IDP
Michael Yee
UBS
UBS
€195.2
Buy
29.69%
Upside
Reiterated
05/15/26
Biogen Buy Rating Reiterated as Tau Data Eases Overhang; Price Target Maintained at $225
H.C. Wainwright Analyst forecast on DE:IDP
Andrew Fein
H.C. Wainwright
H.C. Wainwright
€205.61
Buy
36.60%
Upside
Reiterated
05/14/26
Biogen Buy Rating Reiterated as CELIA Phase 2 Diranersen Data De-Risk Tau Strategy and Support Unchanged $237 Price Target
Bank of America Securities Analyst forecast on DE:IDP
Jason Zemansky
Bank of America Securities
Bank of America Securities
€176.12
Hold
17.01%
Upside
Reiterated
05/14/26
Biogen Rated Hold as Analyst Cites Mixed Alzheimer’s Data and Commercial Hurdles; $203 Price Target Reiterated
Morgan Stanley Analyst forecast on DE:IDP
Terence Flynn
Morgan Stanley
Morgan Stanley
€178.72
Hold
18.73%
Upside
Reiterated
05/14/26
Hold Rating Maintained on Biogen as BIIB080 Moves to Phase 3; Risk-Reward Seen Balanced with Unchanged $206 Price Target
TD Cowen Analyst forecast on DE:IDP
Phil Nadeau
TD Cowen
TD Cowen
€186.53
Buy
23.92%
Upside
Reiterated
05/14/26
TD Cowen Sticks to Their Buy Rating for Biogen (BIIB)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

3 Months
Salveen RichterGoldman Sachs
Success Rate
15/26 ratings generated profit
58%
Average Return
+1.25%
Copying Salveen Richter's trades and holding each position for 3 Months would result in 57.69% of your transactions generating a profit, with an average return of +1.25% per trade.
1 Year
Myles MinterWilliam Blair
Success Rate
14/22 ratings generated profit
64%
Average Return
+12.32%
Copying Myles Minter's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +12.32% per trade.
2 Years
Myles MinterWilliam Blair
Success Rate
13/22 ratings generated profit
59%
Average Return
+5.35%
Copying Myles Minter's trades and holding each position for 2 Years would result in 59.09% of your transactions generating a profit, with an average return of +5.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDP Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
24
22
31
40
36
Hold
31
38
40
39
30
Sell
2
1
1
1
0
Strong Sell
0
0
0
0
0
total
57
61
72
80
66
In the current month, IDP has received 36 Buy Ratings, 30 Hold Ratings, and 0 Sell Ratings. IDP average Analyst price target in the past 3 months is 191.42.
Each month's total comprises the sum of three months' worth of ratings.

IDP Financial Forecast

IDP Earnings Forecast

Next quarter’s earnings estimate for IDP is €2.76 with a range of €2.02 to €3.70. The previous quarter’s EPS was €3.10. IDP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IDP has Performed in-line its overall industry.
Next quarter’s earnings estimate for IDP is €2.76 with a range of €2.02 to €3.70. The previous quarter’s EPS was €3.10. IDP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IDP has Performed in-line its overall industry.

IDP Sales Forecast

Next quarter’s sales forecast for IDP is €2.11B with a range of €1.92B to €2.30B. The previous quarter’s sales results were €2.09B. IDP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IDP has Performed in-line its overall industry.
Next quarter’s sales forecast for IDP is €2.11B with a range of €1.92B to €2.30B. The previous quarter’s sales results were €2.09B. IDP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IDP has Performed in-line its overall industry.

IDP Stock Forecast FAQ

What is DE:IDP’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen Inc.’s 12-month average price target is 191.42.
    What is DE:IDP’s upside potential, based on the analysts’ average price target?
    Biogen Inc. has 27.17% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Biogen Inc. a Buy, Sell or Hold?
          Biogen Inc. has a consensus rating of Moderate Buy, which is based on 16 buy ratings, 9 hold ratings and 1 sell ratings.
            What is Biogen Inc.’s share price target?
            The average share price target for Biogen Inc. is 191.42. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €238.58 ,and the lowest forecast is €130.14. The average share price target represents 27.17% Increase from the current price of €150.52.
              What do analysts say about Biogen Inc.?
              Biogen Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 26 Wall Streets Analysts.
                How can I buy shares of Biogen Inc.?
                To buy shares of DE:IDP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.